Parathyroid hormone treatment for osteoporosis

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 15, Issue 6, 2008, Pages 495-501

  Cosman, Felicia ^a,b  

^a Columbia University ^*  (United States)

^b HELEN HAYES HOSPITAL   (United States)

Author keywords

Anabolic; Combination therapy; Parathyroid hormone; Sequential therapy; Teriparatide

Indexed keywords

ALENDRONIC ACID; GLUCOCORTICOID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID;

ADD ON THERAPY; CLINICAL TRIAL; CYTOARCHITECTURE; DOSE TIME EFFECT RELATION; DRUG DOSE REGIMEN; DRUG DOSE SEQUENCE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FRACTURE; HUMAN; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; REVIEW;

ANABOLIC AGENTS; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG THERAPY, COMBINATION; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; OSTEOPOROSIS; PARATHYROID HORMONE; RALOXIFENE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 56749150758     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e32831a46d6     Document Type: Review

References (55)

1. McClung MR, San Martin J, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 2005; 165:1762-1768.
2. Arlot M, Meunier PJ, Boivin G, et al. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 2005; 20:1244-1253.
3. Lindsay R, Cosman F, Zhou H, et al. A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J Bone Miner Res 2006; 21:366-373.
4. Jiang Y, Zhao JJ, Mitlak BH, et al. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003; 18:1932-1941.
5. Dempster DW, Cosman F, Kurland ES, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001; 16:1846-1853.
6. Parfitt AM. PTH and periosteal bone expansion. J Bone Miner Res 2002; 17:1741-1743.
7. Burr DB. Does early PTH treatment compromise bone strength? The balance between remodeling, porosity, bone mineral, and bone size. Curr Osteoporos Rep 2005; 3:19-24.
8. Lindsay R, Zhou H, Cosman F, et al. Effects of a one-month treatment with parathyroid hormone (1-34) on Bone formation on cancellous, endocortical and periosteal surfaces of the human ilium. J Bone Miner Res 2007; 22:495-502.
9. Rehman Q, Lang TF, Arnaud CD, et al. Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 2003; 14:77-81.
10. Zanchetta JR, Bogado CE, Ferretti JL, et al. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 2003; 18:539-543.
11. Uusi-Rasi K, Semanick LM, Zanchetta JR, et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone 2005; 36:948-958.
12. Body JJ, Gaich GA, Scheele WH, et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002; 87:4528-4535.
13. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344:1434-1441.
14. Vahle JL, Long GG, Sandusky G, et al. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 2004; 32:426-438.
15. Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 2002; 30:312-321.
16. Harper KD, Krege JH, Marcus R, Mitlak BH. Osteosarcoma and teriparatide? J Bone Miner Res 2007; 22:334.
17. Marcus R, Wang O, Satterwhite J, Mitlak B. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 2003; 18:18-23.
18. Chen P, Satterwhite JH, Licata AA, et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 2005; 20:962-970.
19. Dobnig H, Sipos A, Jiang Y, et al. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 2005; 90:3970-3977.
20. Cosman F, Nieves J, Woelfert L, et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001; 16:925-931.
21. Kurland ES, Cosman F, McMahon DJ, et al. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000; 85:3069-3076.
22. •] are of key importance because they provide evidence of greater strength improvement with teriparatide compared with a potent antiresorptive agent (alendronate). As it is unlikely that a fracture endpoint trial will ever be done comparing these agents, this evidence is critical in providing justification for choosing teriparatide over antiresorptive therapy in many patients with osteoporosis.
23. •] are of key importance because they provide evidence of greater strength improvement with teriparatide compared with a potent antiresorptive agent (alendronate). As it is unlikely that a fracture endpoint trial will ever be done comparing these agents, this evidence is critical in providing justification for choosing teriparatide over antiresorptive therapy in many patients with osteoporosis.
24. Hodsman AB, Hanley DA, Ettinger MP, et al. Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 2003; 88:5212-5220.
25. Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007; 146:326-339. This is an important paper because it is the largest of the PTH(1-84) trials and the only one using this compound that we are likely to see with fracture data. It showed reductions in vertebral but not nonvertebral fracture incidence with PTH(1-84) treatment.
26. Black DM, Bouxsein ML, Palermo L, et al. Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling. J Clin Endocrinol Metab 2008; 93:2166-2172.
27. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003; 349:1207-1215.
28. Neer R, Hayes A, Rao A, et al. Effects of parathyroid hormone, alendronate or both on bone density in osteoporotic postmenopausal women. J Bone Miner Res 2002; 17:S135.
29. Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003; 349:1216-1226.
30. Cosman F, Nieves J, Woelfert L, et al. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J Bone Miner Res 1998; 13:1051-1055.
31. Cosman F, Nieves J, Zion M, et al. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 2005; 353:566-575.
32. Cosman F, Wermers RA, Recknor C, et al. Efficacy of adding teriparatide versus switching to teriparatide in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate. In: ASBMR abstract; 2007. This is an extremely important study because it helps understand some of the differences in results of trials in which PTH is used after antiresorptive therapy. It suggests that teriparatide effects on BMD might be enhanced in those patients on prior therapy who continue their antiresorptive agent when starting teriparatide.
33. Keaveny TM, Hoffmann PF, Singh M, et al. Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. J Bone Miner Res 2008 [Epub ahead of print].
34. Keaveny TM, Hoffmann PF, Singh M, et al. Femoral bone strength after two years of treatment of PTH, alendronate, or PTH + alendronate: finite element Analysis of the PaTH study. In: American Society of Bone and Mineral Research, Philadelphia, Pennsylvania; 2006.
35. Deal C, Omizo M, Schwartz EN, et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 2005; 20:1905-1911.
36. Adami S, San Martin J, Munoz-Torres M, et al. Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis. Osteoporos Int 2008; 19:87-94. This study is important because it demonstrates the variability in magnitude of teriparatide effect across the skeleton with teriparatide. It also provides additional clinical trial evidence of the need to start an antiresorptive agent after teriparatide to obtain optimal effects.
37. Cosman F, Nieves JW, Zion M, et al. Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy. Osteoporos Int 2008; 19:529-535.
38. Ettinger B, San Martin J, Crans G, Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004; 19:745-751.
39. Obermayer-Pietsch BM, Marin F, McCloskey EV, et al. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 2008; 23:1591-1600.
40. Boonen S, Marin F, Obermayer-Pietsch B, et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2008; 93:852-860.
41. Wermers RA, Recknor CP, Cosman F, et al. Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate. Osteoporos Int 2008; 19:1055-1065.
42. Miller PD, Delmas PD, Lindsay R, et al. Early responsiveness of women with osteoporosis to teriparatide following therapy with alendronate or risedronate. J Clin Endocrinol Metab 2008; 93:3785-3793.
43. Lindsay R, Nieves J, Formica C, et,al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997; 350:550-555.
44. Misof BM, Roschger P, Cosman F, et al. Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab 2003; 88:1150-1156.
45. Roe EB, Sanchez S, del Puerto GA. Parathyroid hormone 1-34(hPTH 1-34) and estrogen produce dramatic bone density increases in postmenopausal ostoeporosis results from a placebo-controlled randomized trial. J Bone Miner Res 1999; 12:S137.
46. Ste-Marie LG, Schwartz SL, Hossain A, et al. Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy. J Bone Miner Res 2006; 21:283-291.
47. Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003; 18:9-17.
48. Kaufman JM, Orwoll E, Goemaere S, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 2005; 16:510-516.
49. Lane NE, Sanchez S, Modin GW, et al. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res 2000; 15:944-951.
50. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357:2028-2039. This extremely important study compares BMD and fracture effects of teriparatide vs. alendronate in glucocorticoid-induced osteoporosis. Results show dramatic reductions in vertebral fracture occurrence in the teriparatide vs. alendronate group. This is probably the only fracture endpoint trial that will ever be done between these two potent agents.
51. Kurland ES, Heller SL, Diamond B, et al. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos Int 2004; 15:992-997.
52. Lindsay R, Scheele WH, Neer R, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 2004; 164:2024-2030.
53. Rittmaster RS, Bolognese M, Ettinger MP, et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 2000; 85:2129-2134.
54. Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005; 353:555-565.
55. Cosman F, Nieves J, Zion M, et al. Effects of PTH(1-34) rechallenge 1 year after the first PTH course in patients in long-term alendronate. J Bone Miner Res 2005; 20:S21.